Latest news
18 November 2018
Touchlight appoints Dr. Michael Linden as Chief Scientific Officer
Touchlight Genetics Ltd, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announced the appointment of Dr. Michael Linden as Chief Scientific Officer (CSO). In his role Dr. Linden will be responsible for leading the Company’s discovery pipeline and translational research efforts in genetic medicine, deploying their doggybone DNA technology … Continued
2 November 2018
Touchlight awarded runner-up in Spectator Economic Disruptor Award
Earlier this year, The Spectator and Julius Baer launched the inaugural Economic Disruptor Awards to celebrate the most creative entrepreneurs in the UK. Over the past six months, over 100 nominations have been reviewed. On the 1st of November, the winners were announced at a gala dinner hosted by Andrew Neil, Chairman of The Spectator, and attended by … Continued
24 October 2018
Touchlight announces collaboration with Janssen Biotech
Hampton, London, United Kingdom, 23rd October 2018 Touchlight Genetics Ltd., a biotechnology company developing a novel, synthetic DNA vector platform known as “doggybone” DNA, announced a collaboration with Janssen Biotech, Inc. to evaluate the application of doggybone DNA in the development of multiple genetic therapies, in the fields of infectious disease and oncology. The agreement … Continued
27 March 2018
Touchlight opens GMP production facility
Touchlight Genetics Ltd has established a GMP facility to support development of therapeutic products that incorporate the company’s revolutionary dbDNA™ vector technology. The facility will support clinical and commercial production for both in-house and partnered programs. Touchlight has developed a revolutionary DNA vector known as doggybone™ DNA (dbDNA) which enables uniquely differentiated products across multiple … Continued